Akebia, Otsuka in deal for CKD candidate vadadustat

Akebia Therapeutics Inc. (NASDAQ:AKBA) jumped $1.62 (19%) to $9.97 on Tuesday after it granted Otsuka Pharmaceutical Co.

Read the full 172 word article

User Sign In